farm-animal-healthcare-market
Published

August 2017

Farm Animal Healthcare Market by Products (vaccines, paraciticides, anti-infectives, medicinal feed additives, and other pharmaceuticals), By diagnostic technologies, by Animal Typ

Purchase Report
$4250
Single user license
$4500
Team license
$8750
Corporate license

GLOBAL FARM ANIMAL HEALTH MARKET

The global farm animal healthcare market accounted for around 53% of the entire veterinary healthcare market. The population of traditional farm animals, especially poultry and ruminants, has doubled in the last decade with the growing population to feed. The growing demand for fresh meat and dairy products has turned the focus on animal nutrition, thus, driving the market in spite of hindrances like shortage of veterinarians in emerging markets. The market is projected to increase by more than 56%, globally, at a CAGR of over 7.83%, during 2017-2022 (the forecast period).

ANIMAL HEALTH VACCINE OPPORTUNITIES EXPAND WITH AGRILABS ACQUISITIONS

AgriLabs entered into the vaccine manufacturing business with a new USDA-licensed facility in Lincoln, Nebraska. AgriLabs acquired Lincoln-based Antelope Valley Bios and Benchmark Biolabs, and Benchmark’s ownership interest of VaxLiant. With these moves, AgriLabs, along with its new business subsidiaries, currently offers complete concept-to-commercialization services for vaccines used in swine, cattle, poultry, and other species. The swine market will be the first target for the new facilities, with a focus on custom-made vaccines.

ENHANCED ANIMAL HEALTH = BETTER HUMAN HEALTH

In the last decade, the global demand and consumption of meat have increased exponentially. With the focus on ensuring their protection from various infectious diseases, the administration of several drugs has also seen phenomenal growth. High demand for proteins obtained from animals, coupled with unfortunate events such as an outbreak of bird flu and avian influenza that require immediate drug administration, is aiding the growth of adoption rate of farm animal drugs. Moreover, the growth in demand for specific meat in several regions is accelerating the global farm animal drugs market. For instance, growing demand for horse meat in Eastern Europe, as a viable substitute to cattle meat, is increasing the livestock in Brazil, and poultry farming in Australia. Asia-Pacific is known for its growing animal industry, which is affected by a number of diseases that necessitate treatment, which, in turn, drives the farm animal drugs market in this region. Livestock has always played an important role, alongside the ascent of humans on this planet. This interdependence is unlikely to change in the foreseeable future, so the demand for animal healthcare should continue to rise. As companies operating in this space continue to innovate and come up with new treatments and solutions, this expanding market ought to enjoy persistent strength.

VETERINARY PARASITICIDES TO SEE A GREAT SURGE IN DEMAND

Veterinary pharmaceuticals, including parasiticides, have transformed the health of livestock animals across the globe, over the last two decades. As of 2017, the spectrum of parasiticides for veterinary applications continues to expand with a variety of ectoparasiticides, endoparasiticides, and endectocides that are launched every year. Demand for endoparasiticides is more, as they control an increasing prevalence of internal parasiticides, such as roundworms, tapeworms and flukes, which, in turn, fuels the growth of parasiticides segment of veterinary healthcare for farm animals. Constant innovations are leading to the emergence of novel parasiticides delivery systems as well growth of the market.

MAJOR PLAYERS FOCUS ON CONSUMER’S RISING PREFERENCE FOR ANTIBIOTIC & HORMONE-FREE DRUGS

The leading global players, such as Merck, Lilly, and others, seek alternatives to antibiotics in veterinary drugs. The voluntary FDA guidelines that are made mandatory in early 2017 is acting as a great support for these players. These developments in the market will lead to less reliance on antibiotics for animals. In this context, a new research center in the United States, built and operated by Elanco LLC, a unit Eli Lilly & Co., is concentrating exclusively on developing vaccines as alternatives. The strategy of the drug industry is to partner with the medical establishments to reduce the use of antibiotics, as resistant super-bugs become more prevalent in hospitals, nursing homes, and other public spaces.

Weaning animals from antibiotics in favor of vaccines has become central to that effort. The feed of farm animals contains about 72% of the US antibiotics, which make their way into the human body. Therefore, it highlights a clear link between the health of the livestock and human population. Around 6.18 lakh people die annually from drug-resistant infections, with millions more falling sick. The prevalent use of antibiotics in animals plays a role in those deaths because they allow super-bugs to flourish.  Farmers and ranchers are not in the favor of giving up antibiotics as these drugs are cheap and easy to administer. However, change is coming because voluntary FDA rules have become mandatory in January 2017. These rules include the prohibition of labels claiming the use of antibiotic-based growth promoters.

Some of the Key Players in the Global Farm Animal Health Market include:

  • Zoetis
  • Merck
  • Merial
  • Elanco
  • Bayer HealthCare
  • Virbac
  • Novartis
  • Boehringer Ingelheim
  • Heska Corporation
  • Bioniche Animal Health Canada, Inc.
  • Ceva
RELATED REPORTS

Confused about which report to get?

Download a full report to understand our capabilities
Purchase Report
$4250
Single user license
$4500
Team license
$8750
Corporate license
Our Clients Include View All

Looking to Customize Report?